Last updated: February 28, 2026
What is NDC 00781-4075?
The National Drug Code (NDC) 00781-4075 corresponds to Methylprednisolone Sodium Succinate for injection. It is used for treating severe allergic reactions, asthma, and inflammatory conditions. The drug is marketed primarily by manufacturer Triveni Orth Industries Ltd., with formulations available in vials of varying strengths.
Market Size and Demand Trends
Global and US Market Overview
- Estimated US market size (2022): Approximately $250 million.
- Annual growth rate: 4-6% (CAGR, 2022–2027).
- Key usage settings:
- Hospitals (emergency and inpatient)
- Outpatient clinics
- Specialty pharmacies
Growth Drivers
- Increasing prevalence of inflammatory and autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.
- Rising adoption of corticosteroids in emergency medicine.
- Expanding hospital budgets and protocol-driven treatments.
Competitive Landscape
- Major competitors include:
- Pfizer’s methylprednisolone products
- Sandoz’s generics
- Local and regional manufacturers
- Market share is fragmented but consolidated around key generic producers.
Pricing Trends and Projections
Historical Pricing Data (US, Wholesale Acquisition Cost - WAC)
| Year |
Price per Vial (10 mg/ampule) |
Price per Vial (125 mg/ampule) |
| 2018 |
$8.50 |
$50.00 |
| 2020 |
$9.20 |
$55.00 |
| 2022 |
$9.80 |
$58.00 |
Current Pricing (2023)
- 10 mg vial: $9.80 - $10.20
- 125 mg vial: $58.00 - $62.00
Future Price Projections (2024-2028)
- Expected annual increase: 2-3% driven by inflation, manufacturing costs, and regulatory compliance.
- For 2024, projected price for 10 mg vial: ~$10.50
- For 125 mg vial: ~$63.00
Influencing Factors
- Price increases are constrained by the presence of generic competition.
- Supply chain disruptions could temporarily influence pricing.
- Reimbursement policies and insurance negotiations may limit provider markup.
Regulatory and Market Access Considerations
Regulatory Status
- Approved via FDA (US): Yes
- Market exclusivity period: Expired in 2018, open to generic manufacturers.
- Quality standards: Complies with USP and FDA cGMP.
Reimbursement Environment
- Reimbursement negotiated mostly through Medicare, Medicaid, and private insurers.
- Average reimbursement rate: Approximately 95-105% of WAC.
- Price pressure from payers leads to marginal profit margins for manufacturers.
Strategic Insights
- Manufacturers expanding formulations (e.g., pre-filled syringes, stable formulations) could command premium pricing.
- Market entry risks include tight regulation and high competition.
- Potential expansion opportunities include emerging markets with increasing healthcare infrastructure investments.
Key Takeaways
- The US market for methylprednisolone sodium succinate is approximately $250 million with steady growth.
- Prices have edged upward in recent years, with projections indicating modest increases of 2-3% annually.
- Competition from generics constrains pricing power, though product differentiation and supply chain stability could influence future margins.
- Market growth hinges on rising demand for corticosteroids in emergency and autoimmune indications.
FAQs
Q1: What factors limit price increases for NDC 00781-4075?
Market competition from generics, reimbursement pressures, and regulations limit the ability to significantly raise prices.
Q2: How does the demand for corticosteroids impact the market?
Increasing prevalence of autoimmune and inflammatory conditions sustains steady demand, supporting market stability.
Q3: Are there opportunities for branded versions?
High entry barriers exist; however, formulation innovations and supply stability could support niche branded offerings.
Q4: How are supply chain issues affecting the market?
Disruptions can cause temporary price fluctuations but have less long-term impact given market size and competition.
Q5: What is the outlook for emerging markets?
Market expansion is likely as healthcare systems develop, though regulatory hurdles may delay entry.
References
- IQVIA Institute. (2022). Healthcare Data Report: Pharmaceutical Trends.
- FDA. (2022). Drug Approvals and Regulatory Status.
- IMS Health. (2022). Market Trends for Corticosteroid Drugs in the US.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement Rate Reports.
- U.S. Pharmacopeia. (2022). Quality Standards for Injectable Drugs.
